MORAb-202, an Antibody Drug Conjugate Utilizing Humanized Anti-Human FRa Farletuzumab and the Microtubule-Targeting Agent Eribulin, Has Potent Anti-Tumor Activity

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-17-1215

Related search